Trials / Completed
CompletedNCT02191280
Antistax® in Patients With Chronic Venous Insufficiency
The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 25 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study to determine the efficacy and tolerability of two dose levels of Antistax relative to placebo in patients suffering from CVI grade I or incipient grade II
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antistax®, low dose | |
| DRUG | Antistax®, high dose | |
| DRUG | Placebo |
Timeline
- Start date
- 1998-04-01
- Primary completion
- 1998-09-01
- First posted
- 2014-07-16
- Last updated
- 2014-07-16
Source: ClinicalTrials.gov record NCT02191280. Inclusion in this directory is not an endorsement.